Acute inhalation toxicity testing: Considerations of technical and regulatory aspects

被引:9
|
作者
Pauluhn, J
Bury, D
Fost, U
Gamer, A
Hoernicke, E
Hofmann, T
Kunde, M
Neustadt, T
Schlede, E
Schnierle, H
Wettig, K
Westphal, D
机构
[1] HOECHST AG,D-6230 FRANKFURT,GERMANY
[2] BUNDESANSTALT ARBEITSSCHUTZ,DORTMUND,GERMANY
[3] BASF AG,D-6700 LUDWIGSHAFEN,GERMANY
[4] BUNDESINST GESUNDHEITLICHEN VERBRAUCHERSCHUTZ & V,BERLIN,GERMANY
[5] FED BIOL RES CTR AGR & FORESTRY,BRAUNSCHWEIG,GERMANY
关键词
classification and transportation requirements; limit tests; Haber's rule limit test;
D O I
10.1007/s002040050351
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
The EU regulatory statute for the acute hazard identification of chemicals requires selection of the two most appropriate routes of administration. Testing employing the oral route is mandatory, whereas selection of the dermal or inhalation route requires expert judgement, i.e. considerations of structural alerts with regard to the inherent acute inhalation toxicity as well as the likelihood of dermal and inhalation exposure, respectively. Currently, testing of chemicals requires acute inhalation exposure of 4-h and l-h durations according to EU classification and labelling and UN Transport Guidelines, respectively. The analysis made revealed that l-h exposures appear to add little knowledge in addition to existing 4-h LC(50) values and a default value of 4 should be used for conversion of 4-h to l-h LC(50) values, independently of the physical state of the chemical. Therefore: also the unit of concentration of exposure atmospheres should be independent of nominal features of the test substance. Hence, the preferred dose metric is mass (mg/litre air) rather than volume (ppm). Taking into account the overall variability of acute toxicity data the recommendations given are classification into the following groups of 4-h LC(50) values: less than or equal to 0.05, >0.05-0.2, >0.2-1, >1-5 and >5.0 mg/l. No distinction should be made concerning vapours and aerosols with regard to units and conversion factors from 4-h to l-h LC(50) values and the default factor of 4 appears to be most suitable. Further differentiation of classification is not indicated due to technical variability of acute inhalation testing and resolution of the acute bioassay.
引用
收藏
页码:1 / 10
页数:10
相关论文
共 50 条
  • [31] TESTING OF INDUSTRIAL-CHEMICALS FOR INHALATION TOXICITY
    HARDY, CJ
    COLLINS, C
    CHEMISTRY & INDUSTRY, 1981, (03) : 89 - 92
  • [32] Quality assurance for nanomaterial inhalation toxicity testing
    Lee, Sung Kwon
    Jo, Mi Seong
    Kim, Hoi Pin
    Kim, Jong Choon
    Yu, Il Je
    INHALATION TOXICOLOGY, 2021, 33 (05) : 161 - 167
  • [33] Association of Inhalation Toxicologists' (AIT) review of regulatory aspects for inhalation toxicology studies
    Jones, David R.
    Baldrick, Paul
    INHALATION TOXICOLOGY, 2013, 25 (02) : 84 - 90
  • [34] Regulatory and technical tailings design considerations in Chile
    Krause, AJ
    TAILINGS AND MINE WASTE '97, 1997, : 51 - 55
  • [35] Regulatory and technical considerations for life cycle management
    Lute, Scott
    Agarabi, Cyrus
    Brorson, Kurt
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 251
  • [36] Clinical and regulatory considerations in pharmacogenetic testing
    Schuck, Robert N.
    Marek, Elizabeth
    Rogers, Hobart
    Pacanowski, Michael
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2016, 73 (23) : 1999 - 2006
  • [37] Evaluation of acute inhalation toxicity for chemicals with limited toxicity information
    Grant, Roberta L.
    Kadlubar, Bernard J.
    Erraguntla, Neeraja K.
    Honeycutt, Michael
    REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2007, 47 (03) : 261 - 273
  • [38] ACUTE TOXICITY TESTING
    FRAZIER, JM
    JOURNAL OF THE SOCIETY OF COSMETIC CHEMISTS, 1986, 37 (01): : 45 - 45
  • [39] Practical, regulatory and clinical considerations for development of inhalation drug products
    Hou, Shuguang
    Wu, Jiangyue
    Li, Xu
    Shu, Hong
    ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2015, 10 (06) : 490 - 500
  • [40] TECHNICAL ASPECTS OF CELL COLLECTION - DONOR CONSIDERATIONS
    HUESTIS, DW
    CLINICAL ONCOLOGY MONOGRAPHS, 1983, 2 (03): : 529 - 547